Agarwal N et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18(4):425-36. Abstract
Armstrong AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40(15):1616-22. Abstract
Attard G et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022;399(10323):447-60. Abstract
Bögemann M et al. Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: Planned subgroup analysis of the phase 3 ARAMIS Trial. Eur Urol 2022;[Online ahead of print]. Abstract
Cathomas R et al. Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16). ESMO 2021;Abstract LBA26.
Chi KN et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294-303. Abstract
Chi KN et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Gastrointestinal Cancers Symposium 2022;Abstract 12.
Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence 2022;1(9). Abstract
Colomba E et al. ODENZA, A French prospective randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). ASCO 2021;Abstract 5046.
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
Fizazi K et al. Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS. Gastrointestinal Cancers Symposium 2022;Abstract 256.
Fizazi K et al. Quality of life and patient-relevant endpoints with darolutamide in the phase III ARSENS study. ESMO 2022;Abstract 1360MO.
Gillessen S et al. Invited discussant LBA9. ESMO 2022;Discussant LBA9.
Halabi S et al. Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). ESMO 2022;Abstract 1375P.
Haresh KP et al. A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE). ASCO GU 2022;Abstract TPS200.
Kishan AU et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localized prostate cancer: An individual patient data meta-analysis. Lancet Oncol 2022;23(2):304-16. Abstract
McKay R et al. CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). ESMO 2022;Abstract 1423TiP.
Merseburger AS et al. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. Gastrointestinal Cancers Symposium 2022;Abstract 15.
Parker CC et al. Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial. ESMO 2022;Abstract LBA9.
Pollock Y et al. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prost Cancer Prostatic Dis 2022;[Online ahead of print]. Abstract
Rao A et al. Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC). ASCO 2022;Abstract TPS5107.
Saad F et al. Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. ASCO 2022;Abstract 5078.
Saad F et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Gastrointestinal Cancers Symposium 2022;Abstract 11.
Saad F et al. Relugolix: A novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol 2021;13:1-12. Abstract
Shore ND et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020;382(23):2187-96. Abstract
Smith MR et al. CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. Gastrointestinal Cancers Symposium 2022;Abstract TPS198.
Smith MR. Darolutamide in metastatic prostate cancer. Reply. N Engl J Med 2022;386(24):2345. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: A patient and caregiver perspective and plain language summary of the ARASENS trial. Future Oncol 2022;18(21):2585-97. Abstract
Smith MR et al. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol 2021;19(10):627-30. Abstract
Smith MR et al. Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARSENS trial. Gastrointestinal Cancers Symposium 2022;Abstract 13.